Mobile Menu - OpenMobile Menu - Closed

Committee to Hold Hearing on Gilead’s Exorbitant Price for HIV Prevention Drug

May 14, 2019
Press Release

Washington, D.C. (May 14, 2019)—On Thursday, May 16, 2019, at 10:00 a.m., the Committee on Oversight and Reform will hold a hearing on “HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments.” 

 

WHERE:  2154 Rayburn House Office Building

 

WHEN:  Thursday, May 16, 2019

 

TIME:  10:00 a.m.

 

A livestream will broadcast here

 

PURPOSE AND BACKGROUND

 

The hearing will examine the Gilead’s pricing for an HIV prevention drug known as Truvada for pre-exposure prophylaxis (PrEP).  The hearing also will examine taxpayer funding that led to approval by the Food and Drug Administration (FDA) and whether the public is receiving an appropriate return on its investment.

 

In 2012, the FDA approved the use of Truvada for PrEP, a daily pill that prevents the transmission of HIV.  In the United States, Truvada is currently sold at a list price of approximately $2,100 per month, generating $3 billion in revenue for Gilead in 2018 alone. Generic Truvada is available in other countries at a fraction of the cost, but no generic version is offered in the United States.

 

During the State of the Union, President Trump unveiled his “Ending the HIV Epidemic” initiative, which seeks to reduce new HIV infections by 90 percent in the next ten years.  A critical component of his plan is to expand the use of PrEP among at-risk populations. However, the high price of Truvada may hamper the government’s ability to achieve this objective.

 

On May 9, 2019, Health and Human Services Secretary Alex Azar announced that Gilead agreed to donate up to 2.4 million vials of PrEP each year for up to 11 years.  The medication will be distributed to approximately 200,000 individuals who are uninsured and at high risk of HIV transmission.  However, there are approximately 1.1 million Americans who are “at substantial risk for HIV and should be offered PrEP,” according to the Centers for Disease Control and Prevention.  It remains unclear how the Administration will make up this shortfall, and at what cost.

 

WITNESSES

 

Daniel O’Day

Chairman and Chief Executive Officer

Gilead Sciences, Inc.

 

Dr. Robert Grant

Professor of Medicine

University of California, San Francisco

 

Dr. Rachelle Walensky, MD, MPJ

Chief, Division of Infectious Diseases, Massachusetts General Hospital

Professor of Medicine, Harvard Medical School

 

Tim Horn

Director, Medication Access and Pricing

National Alliance of State and Territorial AIDS Directors

 

Dr. Aaron Lord

PrEP Patient and Advocate

 

 

116th Congress